The novel isoflavonoids inhibit RANKL-induced osteoclast formation

C Chang; C Tang; J Liu

doi:10.1055/s-0030-1264481

Planta Medica, Table of Contents

The novel isoflavonoids inhibit RANKL-induced osteoclast formation

C Chang ¹, C Tang ², J Liu ¹

¹China Medical University, Graduate Institute of Pharmaceutical Chemistry, 1009Rm, No. 1, Hsueh-Shih Rd, Taichung, 404 Taichung, Taiwan
²China Medical University, Department of Pharmacology, 91, Hsueh-Shih Rd, Taichung, 404 Taichung, Taiwan

Abstract

Isoflavonoids are compounds characterised by structurally features which are similar to the mammalian estrogens and have received considerable attention for their preventive actions on bone loss. In the course of this study we synthesized novel isoflavone derivatives and examined the activities in bone cells. We found that the novel isoflavone derivatives markedly inhibited the receptor activator of nuclear factor kappa B ligand (RANKL) plus macrophage colony stimulating factor (M-CSF)-induced osteoclastic differentiation from bone marrow stromal cells and RAW264.7 macrophage cells. Isoflavone derivatives did not affect the cell proliferation and differentiation of human cultured osteoblasts. Our data suggest that the novel isoflavone derivatives inhibit osteoclastogenesis from bone marrow stromal cells and macrophage cells via attenuated of RANKL-induced p38, JNK and NF-kB activation.